These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17786067)

  • 1. A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension.
    Weiss RJ; Weber MA; Carr AA; Sullivan WA
    J Clin Hypertens (Greenwich); 2007 Sep; 9(9):667-76. PubMed ID: 17786067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I-II hypertension.
    Neutel JM; Smith DH; Gradman AH
    J Hum Hypertens; 2010 Jan; 24(1):64-73. PubMed ID: 19404314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nebivolol efficacy and safety in patients with stage I-II hypertension.
    Greathouse M
    Clin Cardiol; 2010 Apr; 33(4):E20-7. PubMed ID: 20162736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
    Giles TD; Weber MA; Basile J; Gradman AH; Bharucha DB; Chen W; Pattathil M;
    Lancet; 2014 May; 383(9932):1889-98. PubMed ID: 24881993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and tolerability of nebivolol in hypertensive African American patients.
    Saunders E; Smith WB; DeSalvo KB; Sullivan WA
    J Clin Hypertens (Greenwich); 2007 Nov; 9(11):866-75. PubMed ID: 17978594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood pressure effects of combined β-blocker and angiotensin-converting enzyme inhibitor therapy compared with the individual agents: a placebo-controlled study with nebivolol and lisinopril.
    Weber MA; Basile J; Stapff M; Khan B; Zhou D
    J Clin Hypertens (Greenwich); 2012 Sep; 14(9):588-92. PubMed ID: 22947356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial.
    Grassi G; Trevano FQ; Facchini A; Toutouzas T; Chanu B; Mancia G
    Blood Press Suppl; 2003 Dec; 2():35-40. PubMed ID: 14761075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of nebivolol in stage I-II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials.
    Weiss RJ; Saunders E; Greathouse M
    Clin Ther; 2011 Sep; 33(9):1150-61. PubMed ID: 21864908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic and antihypertensive effects of nebivolol and atenolol in normometabolic patients with mild-to-moderate hypertension.
    Pesant Y; Marc-Aurèle J; Bielmann P; Alaupovic P; Cartier P; Bichet D; Thibault G; Lupien PJ
    Am J Ther; 1999 May; 6(3):137-47. PubMed ID: 10423656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nebivolol monotherapy in younger adults (younger than 55 years) with hypertension: a randomized, placebo-controlled trial.
    Giles TD; Khan BV; Lato J; Brener L; Ma Y; Lukic T
    J Clin Hypertens (Greenwich); 2013 Sep; 15(9):687-93. PubMed ID: 24034663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nebivolol withdrawal results in blood pressure returning toward pretreatment levels, but without rebound symptoms: phase IV randomized trial.
    Lewin A; Lasseter KC; Dong F; Whalen JC
    J Am Soc Hypertens; 2012; 6(3):228-36. PubMed ID: 22421631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
    Weiss RJ; Stapff M; Lin Y
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of antihypertensive efficacy of carvedilol and nebivolol in mild-to-moderate primary hypertension: a randomized trial.
    Erdoğan O; Ertem B; Altun A
    Anadolu Kardiyol Derg; 2011 Jun; 11(4):310-3. PubMed ID: 21543293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate essential hypertension.
    Roca-Cusachs A; Oigman W; Lepe L; Cifkova R; Karpov YA; Harron DW
    Acta Cardiol; 1997; 52(6):495-506. PubMed ID: 9542575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS).
    Czuriga I; Riecansky I; Bodnar J; Fulop T; Kruzsicz V; Kristof E; Edes I; ;
    Cardiovasc Drugs Ther; 2003 May; 17(3):257-63. PubMed ID: 14574084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Nebivolol monotherapy versus Nebivolol in combination with other antihypertensive therapies for the treatment of hypertension.
    Papademetriou V
    Am J Cardiol; 2009 Jan; 103(2):273-8. PubMed ID: 19121451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of nebivolol and valsartan on BP reduction and sleep apnoea activity in patients with essential hypertension and OSA.
    Heitmann J; Greulich T; Reinke C; Koehler U; Vogelmeier C; Becker HF; Schmidt AC; Canisius S
    Curr Med Res Opin; 2010 Aug; 26(8):1925-32. PubMed ID: 20560730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study.
    Rosei EA; Rizzoni D; Comini S; Boari G;
    Blood Press Suppl; 2003 May; 1():30-5. PubMed ID: 12800985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essential hypertension.
    Gradman AH; Brady WE; Gazdick LP; Lyle P; Zeldin RK
    Clin Ther; 2002 Jul; 24(7):1049-61. PubMed ID: 12182251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.